PDF(Pubmed)
Abstract：
UNASSIGNED: The optimal treatment for recurrent non-small cell lung cancer (NSCLC) has not been standardized. In this prospective cohort study, we evaluated post-recurrence survival (PRS) after treatment of recurrent NSCLC and identified prognostic factors after recurrence.
UNASSIGNED: This multicenter prospective cohort study was conducted in 14 hospitals. The inclusion criteria for this study were patients with recurrence after radical resection for NSCLC. Information about the patient characteristics at recurrence, tumor-related variables, primary surgery, and treatment for recurrence was collected. After registration, follow-up data, such as treatment and survival outcomes, were obtained every 3 months.
UNASSIGNED: From 2010 to 2015, 505 cases were enrolled, and 495 cases were analyzed. As initial treatment for recurrence, 263 patients (53%) received chemotherapy, 46 (9%) received chemoradiotherapy, 98 (20%) had definitive radiotherapy, 14 (3%) received palliative radiotherapy, and 31 (6%) underwent surgical resection. The remaining 43 patients (9%) received supportive care. The median PRS and 5-year survival rates for all cases were 30 months and 31.9%, respectively. The median PRS according to the initial treatment was as follows: supportive care, 8 months; palliative radiotherapy, 16 months; definitive radiotherapy, 30 months; chemotherapy, 31 months; chemoradiotherapy, 35 months; and surgery, not reached. A multivariate analysis showed that the age, gender, performance status, histology presence of symptoms, duration from primary surgery to recurrence, and number of recurrent foci were independent prognostic factors for PRS.
UNASSIGNED: The PRS of patients with recurrent NSCLC was different depending on the patient\'s background characteristics and initial treatment for recurrence.
UNASSIGNED: This multicenter prospective cohort study was conducted in 14 hospitals. The inclusion criteria for this study were patients with recurrence after radical resection for NSCLC. Information about the patient characteristics at recurrence, tumor-related variables, primary surgery, and treatment for recurrence was collected. After registration, follow-up data, such as treatment and survival outcomes, were obtained every 3 months.
UNASSIGNED: From 2010 to 2015, 505 cases were enrolled, and 495 cases were analyzed. As initial treatment for recurrence, 263 patients (53%) received chemotherapy, 46 (9%) received chemoradiotherapy, 98 (20%) had definitive radiotherapy, 14 (3%) received palliative radiotherapy, and 31 (6%) underwent surgical resection. The remaining 43 patients (9%) received supportive care. The median PRS and 5-year survival rates for all cases were 30 months and 31.9%, respectively. The median PRS according to the initial treatment was as follows: supportive care, 8 months; palliative radiotherapy, 16 months; definitive radiotherapy, 30 months; chemotherapy, 31 months; chemoradiotherapy, 35 months; and surgery, not reached. A multivariate analysis showed that the age, gender, performance status, histology presence of symptoms, duration from primary surgery to recurrence, and number of recurrent foci were independent prognostic factors for PRS.
UNASSIGNED: The PRS of patients with recurrent NSCLC was different depending on the patient\'s background characteristics and initial treatment for recurrence.
摘要：
未经批准：复发性非小细胞肺癌（NSCLC）的最佳治疗方法尚未标准化。在这项前瞻性队列研究中，我们评估了复发NSCLC治疗后的复发生存率(PRS),并确定了复发后的预后因素.
未经评估：这项多中心前瞻性队列研究在14家医院进行。本研究的纳入标准为NSCLC根治术后复发的患者。有关复发时患者特征的信息，肿瘤相关变量，初级手术,并收集复发的治疗方法。注册后,后续数据，如治疗和生存结果，每3个月获得一次。
UNASISIGNED：从2010年到2015年，共纳入505例，并对495例病例进行分析。作为复发的初始治疗，263例患者（53%）接受化疗，46人（9%）接受放化疗，98（20％）接受了确定性放疗，14人（3%）接受姑息性放疗，31例(6%)接受手术切除。其余43名患者（9%）接受支持治疗。所有病例的中位PRS和5年生存率分别为30个月和31.9％，分别。根据初始治疗的中位数PRS如下：支持性治疗，8个月；姑息性放疗，16个月；确定性放疗，30个月；化疗，31个月；放化疗，35个月；和手术，没有到达。多变量分析表明，年龄，性别,性能状态，组织学上存在症状，从初次手术到复发的持续时间，复发灶数量是PRS的独立预后因素。
UNASSIGNED：复发NSCLC患者的PRS因患者的背景特征和复发的初始治疗而异。
未经评估：这项多中心前瞻性队列研究在14家医院进行。本研究的纳入标准为NSCLC根治术后复发的患者。有关复发时患者特征的信息，肿瘤相关变量，初级手术,并收集复发的治疗方法。注册后,后续数据，如治疗和生存结果，每3个月获得一次。
UNASISIGNED：从2010年到2015年，共纳入505例，并对495例病例进行分析。作为复发的初始治疗，263例患者（53%）接受化疗，46人（9%）接受放化疗，98（20％）接受了确定性放疗，14人（3%）接受姑息性放疗，31例(6%)接受手术切除。其余43名患者（9%）接受支持治疗。所有病例的中位PRS和5年生存率分别为30个月和31.9％，分别。根据初始治疗的中位数PRS如下：支持性治疗，8个月；姑息性放疗，16个月；确定性放疗，30个月；化疗，31个月；放化疗，35个月；和手术，没有到达。多变量分析表明，年龄，性别,性能状态，组织学上存在症状，从初次手术到复发的持续时间，复发灶数量是PRS的独立预后因素。
UNASSIGNED：复发NSCLC患者的PRS因患者的背景特征和复发的初始治疗而异。
